Sheba R David

Metabolic syndrome (MetS) is a cluster of cardiometabolic abnormalities including central obesity, insulin resistance, dyslipidemia, and hypertension that markedly increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. Lifestyle modification remains the cornerstone of management, but there is growing interest in adjunctive nutraceutical and phytopharmacological approaches capable of safely addressing multiple MetS components. Green tea, derived from the leaves of Camellia sinensis (family Theaceae), is one of the most widely consumed beverages worldwide and is rich in polyphenolic catechins, primarily (−)-epigallocatechin‑3‑gallate (EGCG), which have been extensively investigated for anti-obesity and metabolic benefits. This review provides a pharmacognostic and phytochemical perspective on C. sinensis as an anti-obesity agent in the context of MetS. Pharmacognostic sections summarize macroscopic and microscopic diagnostic features, physicochemical constants, and quality-control parameters for different tea types (green, white, oolong) based on recent standardization studies. Phytochemical sections describe major and minor constituents, with emphasis on catechins, caffeine, theaflavins, thearubigins, and other phenolics, and their quantitative variation by cultivar, processing, and extraction method. Mechanistic evidence from in vitro, animal, and human intervention studies is synthesized to delineate how tea polyphenols modulate body weight, adiposity, lipid and glucose metabolism, blood pressure, and inflammation. Proposed mechanisms include increased energy expenditure and fat oxidation via catechin–caffeine-induced sympathetic stimulation; inhibition of digestive enzymes and nutrient absorption; modulation of lipid metabolism and de novo lipogenesis; activation of AMP‑activated protein kinase (AMPK); improvement of insulin signaling; regulation of adipokine secretion; and remodeling of gut microbiota composition and function. Pharmacokinetic, safety, and formulation aspects are discussed, alongside limitations and variability in clinical trial outcomes. The review concludes that standardized C. sinensis preparations, especially catechin-enriched green tea extracts, represent promising multi-target adjuncts for obesity and MetS management, while highlighting the need for rigorous pharmacognostic standardization, dose–response characterization, and biomarker-driven clinical trials.